Abeona Therapeutics Inc (ABEO NASDAQ) stock market data APIs
$5.4612
0(0%)
as of May 1, 2026
Try our APIs with
free plan!
Abeona Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Prev. Close
5.4612
Open
5.4653
High
5.4928
Low
5.3967
52 wk Range
4-7.5401
Market Cap
309 M
P/E Ratio
5.3762
Shares Outstanding
56 883 K
Revenue
5 820 K
EPS
0
Beta
1.213
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Abeona Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Abeona Therapeutics Inc data using free add-ons & libraries
Get Abeona Therapeutics Inc Fundamental Data
Abeona Therapeutics Inc Fundamental data includes:
- Net Revenue: 5 820 K
- EBITDA: -86 899 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-07
- EPS/Forecast: -0.13
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Abeona Therapeutics Inc News
New
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, May 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awa...
Spotlighting Abeona Therapeutics And 2 More High Growth Stocks Insiders Favor
The United States market has shown robust performance, climbing 3.6% in the last week and 39% over the past year, with earnings projected to grow by 16% annually. In this thriving environment, stocks ...
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, April 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity a...
Abeona Therapeutics Q4 Earnings Call Highlights
Abeona Therapeutics logo Key Points Abeona’s autologous cell therapy ZEVASKYN (approved April 2025) began commercial treatments in December 2025 after a sterility-test delay, with early traction �...
Get Abeona Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
